• FebriDx® granted 510(k) clearance with CLIA waiver, expanding addressable US market to 80 million patients
• Milestone payments of US$5.5 million received from PHASE Scientific and BARDA
• Successful A$20 million placement and SPP offer launched

Lumos Diagnostics reported revenue of US$4.8 million for the third quarter of FY26, up 37% year-over-year. Product revenue was US$2.4 million, primarily from FebriDx® sales, while Services revenue was US$2.4 million. The company received a significant milestone payment of US$5.0 million from PHASE Scientific following the US FDA's granting of 510(k) clearance and CLIA waiver for FebriDx®, which expands the addressable US market to approximately 80 million patients per annum. Lumos also received a US$507,377 milestone payment from BARDA related to the FebriDx® CLIA waiver. Additionally, the company completed a successful A$20 million placement and launched a Share Purchase Plan offer. Lumos continued to progress its Hologic fFN diagnostic product development project, with additional scopes of work added, and commenced a CLIA waived paediatric study for FebriDx® under its BARDA contract. The company reported a net operating cash outflow of US$2.8 million for the quarter, with a cash balance of US$1.1 million at the end of March 2026. Post-quarter, Lumos received the placement proceeds and the PHASE Scientific milestone payment, strengthening its balance sheet.

Lumos expects to receive approximately US$3.4 million in additional non-dilutive milestone payments from Hologic related to the remaining assay feasibility work in Phase 2 and the Phase 3 milestones for the fFN diagnostic product development project.